Trevena is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients affected by Central Nervous System (CNS) conditions. Our lead product candidate is oliceridine injection, a G protein-selective agonist at the mu-opioid receptor being developed for the management of moderate to severe acute pain in hospitals or other controlled clinical settings where intravenous, or IV, opioid therapy is warranted. We are also developing several other product candidates with the potential to address problems across a wide range of therapeutic areas, including migraine, opioid use disorder, and chronic pain.
Our history is rooted in strong science â Trevena was founded to translate Nobel Prize-winning research into a new generation of groundbreaking medicines. Our novel approach to drug discovery has established us as pioneers in acute care medicine.
Source
